Drug shortage: Rocuronium Bromide Injection (ROCURONIUM, ROCURONIUM BROMIDE)
FDA lists 26 presentations as Current. Availability: Unavailable (4), Limited Availability (1), Available (21). Reason: Delay in shipping of the drug; Demand increase for the drug. Companies: Fresenius Kabi USA, LLC, Meitheal Pharmaceuticals, Inc., Mylan Institutional, a Viatris Company, Hikma Pharmaceuticals USA, Inc., Hospira, Inc., a Pfizer Company….
- Published by source
- 2023-02-15
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Fresenius Kabi USA, LLC
- Products
- Rocuronium Bromide Injection ROCURONIUM ROCURONIUM BROMIDE
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Next release November 2026. Check wholesalers for inventory.
- Next release December 2026. Check wholesalers for inventory.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2023-02-15
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #861 | new | 2026-10-22 | 64fca0a48e81…65ee49 | 2343c36ae1e5…1be4a1 |
Chain head: #1094 edf3be25ec2e…478842